Siebolts Udo, Schömig-Markiefka Birgid, Siemanowski-Hrach Janna, Merkelbach-Bruse Sabine
Institut für Pathologie, Medizinische Fakultät und Universitätsklinikum Köln, Universität zu Köln, Köln, Deutschland.
Institut für Pathologie, Universitätsklinikum Köln, Kerpener Str. 62, 50924, Köln, Deutschland.
Pathologie (Heidelb). 2024 Sep;45(5):347-354. doi: 10.1007/s00292-024-01345-2. Epub 2024 Aug 14.
The molecular classification of endometrial carcinoma defines four main groups: polymerase‑ɛ(PolE) gene mutated, microsatellite unstable (MSI), p53 abnormal tumors and tumors with no specific molecular profile (NSMP). This classification provides significant insights into the prognosis and therapeutic decisions. Each group exhibits unique genetic profiles identified through immunohistochemistry and molecular diagnostics, enabling personalized treatment. The identification of these molecular signatures necessitates precise analytical methods, selected based on the local circumstances at each site. The approach to molecular classification highlights the critical role of pathology in the diagnosis and emphasizes the necessity of collaboration between the clinic and pathology.
聚合酶ɛ(PolE)基因突变型、微卫星不稳定(MSI)型、p53异常型肿瘤以及无特定分子特征(NSMP)的肿瘤。这种分类为预后和治疗决策提供了重要见解。每组都表现出通过免疫组织化学和分子诊断确定的独特基因特征,从而实现个性化治疗。这些分子特征的识别需要基于每个地点的当地情况选择精确的分析方法。分子分类方法突出了病理学在诊断中的关键作用,并强调了临床与病理学之间合作的必要性。